DLK2 Antibody

What is DLK2 and why is it important as a research target?

DLK2 (Delta-like 2 homologue) is a protein highly homologous to DLK1 that functions as a non-canonical inhibitor of NOTCH signaling. Recent research has identified DLK2 as significantly upregulated in multiple cancer types, including clear cell renal cell carcinoma (ccRCC), breast cancer, melanoma, and lethal prostate cancers . DLK2 appears to interact with NOTCH receptors, modulating downstream signaling pathways that influence cell proliferation, cell cycle dynamics, apoptosis, and cellular migration. As a potential prognostic biomarker and therapeutic target, particularly in ccRCC, DLK2 represents an important focus for cancer research and novel therapeutic development .

What types of DLK2 antibodies are available for research applications?

While the search results don't specifically detail commercial antibody types, researchers typically utilize several classes of antibodies for DLK2 detection:

• Monoclonal antibodies: Offer high specificity for particular DLK2 epitopes

• Polyclonal antibodies: Recognize multiple epitopes on DLK2 protein

• Domain-specific antibodies: Target particular regions (e.g., extracellular domain vs. intracellular regions)

• Phospho-specific antibodies: Recognize phosphorylated forms of DLK2

• Tagged antibodies: Conjugated with fluorophores or enzymes for direct detection

The optimal antibody selection depends on your experimental objectives, whether for Western blotting, immunohistochemistry, flow cytometry, or immunoprecipitation.

How can I validate the specificity of a DLK2 antibody?

Proper antibody validation is critical for experimental reliability. To validate DLK2 antibody specificity:

• Positive and negative controls: Use tissues or cell lines with known DLK2 expression levels. Research indicates MDA-MB-231 breast cancer cells exhibit DLK2 expression and can be manipulated to express different levels, making them suitable for validation studies .

• Knockout/knockdown verification: Compare antibody reactivity in wild-type versus DLK2 knockout/knockdown samples.

• Peptide competition assay: Pre-incubate antibody with purified DLK2 protein or immunizing peptide before application to samples - specific binding should be blocked.

• Multiple detection methods: Confirm DLK2 detection using alternative techniques (e.g., Western blot plus immunohistochemistry).

• Molecular weight verification: DLK2 should appear at its expected molecular weight in Western blots (with consideration for post-translational modifications).

How do different DLK2 expression levels affect NOTCH signaling detection in experimental models?

The relationship between DLK2 expression levels and NOTCH signaling is complex and dose-dependent. Research in MDA-MB-231 breast cancer cells demonstrates that DLK2 overexpression inhibits NOTCH activation in a dose-dependent manner . When designing experiments to study this relationship:

• Low DLK2 expression levels produce slight inhibition of NOTCH1 activation while potentially enhancing cell invasion and proliferation both in vitro and in vivo .

• High DLK2 expression levels generate stronger inhibition of NOTCH1 activation, which correlates with decreased cell proliferation, increased G0 phase arrest, elevated apoptosis, and reduced migration capability .

To accurately assess these relationships, researchers should:

• Establish cellular models with carefully calibrated DLK2 expression levels

• Quantify NOTCH activation using multiple approaches:

  • Western blot analysis with antibodies specifically detecting the active intracellular domain of NOTCH1 (NICD1)

  • Luciferase reporter assays using NOTCH-dependent promoters containing CSL/RBP-Jk binding sites

  • RT-qPCR analysis of downstream NOTCH target genes like HES1

• Include appropriate controls such as gamma-secretase inhibitors (e.g., DAPT at 10μM) to validate NOTCH inhibition mechanisms .

What are the key considerations when using DLK2 antibodies for studying its prognostic value in cancer?

When investigating DLK2 as a prognostic biomarker, particularly in ccRCC, several methodological considerations are critical:

• Patient stratification: Categorize patients into DLK2-High and DLK2-Low expression groups based on appropriate statistical methods and cutoff values. Studies have shown that DLK2 upregulation is associated with poor survival outcomes in ccRCC patients .

• Clinical correlation: Analyze relationships between DLK2 expression and clinicopathological features. Research indicates DLK2 overexpression associates with advanced stages and high grades in ccRCC, suggesting potential as a prognostic indicator .

• Multivariate analysis: Account for confounding factors when evaluating DLK2's independent prognostic value.

• Tumor microenvironment consideration: Evaluate DLK2's relationship with immune cell infiltration. TIMER analysis has shown associations between macrophage and CD8+ T cell infiltration and good prognosis in ccRCC, with DLK2 overexpression correlating with reduced macrophage recruitment and M1-M2 polarization .

• Validation across multiple cohorts: Confirm findings across independent patient datasets to establish robustness of DLK2 as a prognostic marker.

How can I optimize DLK2 antibody-based detection in tissues with variable expression levels?

Optimizing DLK2 antibody detection across tissues with heterogeneous expression requires:

• Titration experiments: Perform systematic antibody dilution series to identify optimal concentration for specific tissue types. This is particularly important as DLK2 exhibits tissue-specific expression patterns.

• Antigen retrieval optimization: Test multiple antigen retrieval methods (heat-induced vs. enzymatic, various pH buffers) to maximize epitope accessibility without compromising tissue integrity.

• Signal amplification strategies: For tissues with low DLK2 expression, implement tyramide signal amplification or polymer-based detection systems.

• Multiplex staining approaches: Combine DLK2 antibody with markers of relevant pathways (e.g., NOTCH pathway components) or cell types (macrophage markers) for contextual analysis.

• Quantitative image analysis: Employ digital pathology and computational approaches to objectively quantify DLK2 expression across heterogeneous tissue samples.

• Reference standards: Include control tissues with known DLK2 expression levels in each staining batch to ensure consistency.

What are the optimal protocols for detecting DLK2 in Western blot applications?

For effective Western blot detection of DLK2:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • For membrane-associated DLK2, include detergents like NP-40 or Triton X-100

  • Consider phosphatase inhibitors if studying phosphorylated states

• Protein loading:

  • Load 20-50μg total protein per lane

  • Include positive controls (e.g., DLK2-overexpressing cells) and negative controls

• Electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal resolution

  • Transfer to PVDF membranes which typically provide better results for membrane proteins

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST

  • Incubate with primary DLK2 antibody at optimized concentration (typically 1:500-1:2000 dilution)

  • Use appropriate HRP-conjugated secondary antibodies

• Detection considerations:

  • Enhanced chemiluminescence (ECL) systems work well for standard detection

  • For quantitative analysis, consider fluorescent secondary antibodies and digital imaging

• Expected results:

  • Verify bands at the predicted molecular weight

  • Be aware that post-translational modifications may alter apparent molecular weight

Research demonstrates successful DLK2 protein detection in various cell models, including MDA-MB-231 breast cancer cells with different DLK2 expression levels .

How can DLK2 antibodies be utilized to investigate its interaction with NOTCH receptors?

To study DLK2-NOTCH interactions:

• Co-immunoprecipitation (Co-IP):

  • Use DLK2 antibodies to pull down protein complexes, followed by Western blotting for NOTCH receptors

  • Alternatively, immunoprecipitate with NOTCH antibodies and probe for DLK2

  • Include appropriate controls (IgG, lysate inputs)

• Proximity ligation assay (PLA):

  • Employ DLK2 and NOTCH receptor antibodies from different species

  • Secondary antibodies with conjugated oligonucleotides enable visualization of protein-protein interactions in situ

  • Quantify interaction points per cell

• FRET/BRET analysis:

  • Generate fluorescent/bioluminescent fusion proteins for DLK2 and NOTCH

  • Measure energy transfer indicating close proximity

• Surface plasmon resonance:

  • Use purified proteins to quantify binding kinetics and affinity

• Functional validation approaches:

  • Luciferase reporter assays to measure NOTCH signaling activity in the presence of varying DLK2 levels

  • Research shows DLK2 inhibits NOTCH activation as measured by decreased NICD1 levels and reduced activity of NOTCH-dependent luciferase reporters

What techniques can be used to study DLK2's role in immune cell regulation?

Based on research showing DLK2's association with immune cell infiltration in ccRCC , several approaches can be implemented:

• Immunohistochemistry/Immunofluorescence multiplex staining:

  • Co-stain tissue sections with DLK2 antibodies and markers for:

    • Macrophages (CD68, CD163)

    • M1 macrophages (iNOS, CD80)

    • M2 macrophages (CD206, Arginase-1)

    • T cell populations (CD8+, CD4+)

  • Spatial relationship analysis between DLK2+ cells and immune cells

• Flow cytometry:

  • Multi-parameter analysis of DLK2 expression in relation to immune cell markers

  • Sorting of DLK2+ and DLK2- immune cell populations for functional studies

• In vitro co-culture systems:

  • Establish co-cultures of DLK2-expressing cancer cells with immune cells

  • Measure macrophage polarization markers in response to varying DLK2 levels

  • Analyze T cell activation parameters

• Cytokine/chemokine profiling:

  • Measure secreted factors in conditioned media from DLK2-expressing cells

  • Correlate DLK2 expression with cytokine/chemokine patterns

• Computational approaches:

  • TIMER database analysis to correlate DLK2 copy number variation with immune cell recruitment

  • Gene set enrichment analysis for immune-related pathways

How should contradictory findings about DLK2's function be reconciled across different experimental systems?

Research demonstrates that DLK2 can exhibit context-dependent and sometimes contradictory functions:

• Cancer-specific effects:

  • In ccRCC, DLK2 overexpression correlates with poor prognosis

  • In breast cancer, the effects depend on expression levels - low DLK2 expression enhances proliferation while high expression inhibits it

• Signaling pathway complexity:

  • While DLK2 inhibits NOTCH activation, its effects on ERK1/2 MAPK phosphorylation vary by expression level

  • In osteogenesis, DLK2 may promote differentiation by modulating both NOTCH signaling and MAPK pathways

To reconcile these apparent contradictions:

• Carefully document experimental conditions, cell types, and DLK2 expression levels

• Consider the activation states of interacting pathways (NOTCH, MAPK, etc.)

• Acknowledge tissue-specific contextual factors that may influence DLK2 function

• Implement multiple complementary approaches to validate findings

• Develop comprehensive models that incorporate dose-dependent effects observed across studies

What controls are essential when using DLK2 antibodies for quantitative analyses?

For reliable quantitative analysis with DLK2 antibodies:

• Expression level controls:

  • Include samples with known DLK2 expression levels (high, medium, low)

  • Use cell lines with engineered DLK2 expression like HDLK2SL (low expression) and HDLK2SH (high expression) MDA-MB-231 cells

• Technical controls:

  • Loading controls (β-actin, GAPDH) for Western blots

  • Isotype controls for flow cytometry and immunohistochemistry

  • Non-primary antibody controls to assess secondary antibody specificity

• Biological validation controls:

  • DLK2 knockdown/knockout samples

  • Recombinant DLK2 protein standards for absolute quantification

• Standard curves:

  • Generate standard curves using recombinant DLK2 for absolute quantification

  • Ensure linearity within the expected range of experimental samples

• Normalization strategies:

  • For tissue samples, normalize to appropriate housekeeping genes or proteins

  • Consider cell-type specific normalization in heterogeneous tissues

• Inter-assay calibrators:

  • Include identical reference samples across experiments to enable cross-experiment comparisons

How can post-translational modifications of DLK2 affect antibody detection and functional interpretation?

Post-translational modifications (PTMs) present significant considerations for DLK2 antibody applications:

• Potential PTMs affecting DLK2:

  • Glycosylation: As a membrane-associated protein, DLK2 likely undergoes glycosylation

  • Phosphorylation: May occur in regulatory domains affecting signaling

  • Proteolytic processing: Potential for cleavage similar to other NOTCH regulators

• Antibody selection considerations:

  • Determine if your antibody recognizes native, denatured, or modified forms of DLK2

  • Epitope location relative to known or predicted modification sites

  • Consider using multiple antibodies recognizing different epitopes

• Experimental approaches:

  • Enzymatic treatments: Use glycosidases or phosphatases to remove modifications before analysis

  • 2D gel electrophoresis to separate differentially modified forms

  • Mass spectrometry to identify and characterize specific modifications

• Functional implications:

  • Correlate observed modifications with functional outcomes

  • Investigate how modifications affect DLK2's interactions with NOTCH receptors

  • Examine if modifications influence DLK2's subcellular localization

• Interpretation challenges:

  • Apparent molecular weight shifts in Western blots

  • Variable antibody recognition efficiency

  • Heterogeneous staining patterns in tissues

What emerging techniques might enhance DLK2 antibody-based research?

Several cutting-edge approaches show promise for advancing DLK2 antibody applications:

• Single-cell technologies:

  • Single-cell proteomics to measure DLK2 at individual cell resolution

  • Paired single-cell RNA-seq and protein analysis to correlate transcription and protein levels

  • Mass cytometry (CyTOF) for high-dimensional analysis of DLK2 in relation to multiple markers

• Advanced imaging:

  • Super-resolution microscopy to visualize DLK2 localization with nanometer precision

  • Intravital microscopy to track DLK2-expressing cells in vivo

  • Spatial transcriptomics combined with protein detection for contextual understanding

• Engineered antibody formats:

  • Nanobodies with enhanced tissue penetration

  • Bispecific antibodies targeting DLK2 plus interaction partners

  • Antibody fragments for improved access to challenging epitopes

• In situ structural biology:

  • Proximity labeling approaches to map DLK2 interaction networks

  • Conformational sensors to detect active versus inactive DLK2 states

• Computational approaches:

  • AI/machine learning for automated quantification of DLK2 in tissue samples

  • Systems biology models incorporating DLK2 signaling nodes

How might therapeutic targeting of DLK2 be monitored using antibody-based approaches?

As DLK2 emerges as a potential therapeutic target, particularly in cancers like ccRCC , monitoring approaches will be critical:

• Companion diagnostic development:

  • Standardized immunohistochemical protocols for patient stratification

  • Quantitative thresholds for DLK2 positivity correlated with treatment response

• Pharmacodynamic biomarkers:

  • DLK2 protein levels in accessible samples (biopsies, liquid biopsies)

  • Downstream signaling markers (NOTCH activation status, ERK1/2 phosphorylation)

• Resistance monitoring:

  • Detection of DLK2 mutations or conformational changes affecting drug binding

  • Compensatory pathway activation (alternative NOTCH regulators)

• Combination therapy assessment:

  • Multiplex analysis of DLK2 plus related pathway components

  • Immune infiltrate changes in response to DLK2-targeted therapy

• Response prediction models:

  • Integration of DLK2 expression data with other molecular features

  • Machine learning algorithms to predict treatment outcomes based on DLK2 status